We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Assembly Biosciences Inc (ASMB) USD0.001

Sell:$14.45 Buy:$14.95 Change: $0.19 (1.29%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
Change: $0.19 (1.29%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
Change: $0.19 (1.29%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points with the aim of achieving finite treatment and functional cures and research programs focused on the discovery of therapeutics to treat devastating viral diseases, including a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-α (IFN-α) receptor (IFNAR) agonist targeting HBV and HDV. HPIs are antiviral agents in development for HSV-1 and HSV-2, with a clinically validated mechanism of action. Its HBV, HSV-1, and HSV-2 programs include ABI-6250, ABI-5366, and ABI-1179.

Contact details

Two Tower Place, 7Th Floor
United States
+1 (212) 5544388

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$80.55 million
Shares in issue:
5.51 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Jason Okazaki
    President, Chief Executive Officer, Director
  • William Delaney
    Chief Scientific Officer
  • Anuj Gaggar
    Chief Medical Officer
  • Nicole White
    Chief Manufacturing Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.